Cuprina Gains SFDA Classification for MEDIFLY, Names Dr. Enming Yong
Cuprina's 49%-owned MENA unit secured SFDA classification for MEDIFLY as a Medical Device–Drug combination product, clearing scientific and technical requirements for commercial distribution across Saudi Arabia's healthcare system. It also appointed endocrinologist Enming Yong to its Scientific Advisory Board for protocol review, clinical oversight and strategic development.
1. Saudi Classification Enables MEDIFLY Distribution
Cuprina’s 49%-owned associate, Cuprina MENA Co. Ltd, received SFDA classification for MEDIFLY as a Medical Device–Drug combination product. This designation permits the company to finalize scientific and technical requirements and prepare for commercial rollout across Saudi Arabia’s healthcare network.
2. Appointment of Dr. Enming Yong Strengthens Scientific Governance
The company added Dr. Enming Yong, Consultant in Endocrinology at Tan Tock Seng Hospital and Adjunct Senior Lecturer at Lee Kong Chian School of Medicine, to its Medical and Scientific Advisory Board. He will oversee scientific protocol reviews, clinical trial safety, strategic development and trend analysis in chronic wound care.
3. Regional Clinical Engagements Accelerate Adoption
Cuprina sponsored and exhibited MEDIFLY at the 2026 Symposium on Diabetic Wound Healing in Hong Kong and presented its portfolio at Woodlands Health Research Day in Singapore. The inaugural Advisory Board meeting on March 2 further solidified clinical partnerships in key Asian markets.